Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis

New England Journal of Medicine

Volumn 373, Issue 15, 2015, Pages 1418-1428

  Kappos, Ludwig ^a   Wiendl, Heinz ^b   Selmaj, Krzysztof ^c   Arnold, Douglas L ^d   Havrdova, Eva ^e   Boyko, Alexey ^f,g   Kaufman, Michael ^h   Rose, John ^i,j   Greenberg, Steven ^k   Sweetser, Marianne ^l   Riester, Katherine ^l   O'Neill, Gilmore ^l   Elkins, Jacob ^l  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MCGILL UNIVERSITY   (Canada)

^e CHARLES UNIVERSITY   (Czech Republic)

^f PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^g Tyumen Regional Multiple Sclerosis Center   (Russian Federation)

^h UNIVERSITY OF TENNESSEE   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j Salt Lake Veterans Affairs Healthcare System   (United States)

^k ABBVIE INC   (United States)

^l BIOGEN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; DACLIZUMAB; GADOLINIUM; PLACEBO; BETA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; ACNE; ADULT; ANGIONEUROTIC EDEMA; APPENDICITIS; ARTICLE; CELLULITIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DERMATITIS; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATOBILIARY DISEASE; HERPES VIRUS INFECTION; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; INFECTION; INJECTION SITE PAIN; INTENTION TO TREAT ANALYSIS; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RHINOPHARYNGITIS; SEBORRHEIC DERMATITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84943562782     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1501481     Document Type: Article

References (12)

1. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013; 9: 394-404.
2. Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsingremitting multiple sclerosis. Clin Immunol 2012; 142: 9-14.
3. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013; 10: 55-67.
4. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941-6.
5. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012; 4: 145ra06.
6. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 2167-75.
7. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-6.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
9. Neurostatus Systems. Neurostatus training. 2007 (http://www .neurostatus .net).
10. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001; 124: 962-73.
11. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-3.
12. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51: 2117-26.